Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing

Core Insights - Inspira Technologies has achieved a significant milestone in the in-vivo testing of its VORTX technology, demonstrating over 99% gas exchange efficiency at a defined flow rate [1][3][4] - The VORTX technology is designed to provide an advanced alternative for acute respiratory care, potentially reducing the need for invasive mechanical ventilation [2][4] - The in-vivo testing was conducted on an 80 kg swine at a leading preclinical research facility in Israel, confirming the scalability and proof-of-concept for the technology [3][4] Company Overview - Inspira Technologies focuses on developing innovative respiratory support and diagnostic technologies, with its flagship product being the INSPIRA ART500 system [5] - The INSPIRA ART500 aims to allow patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation [5] - The company also has the FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass procedures and is developing the HYLA blood sensor technology for continuous blood monitoring [5]